tammynewton1
14 Jun 2018
Interesting interview for Evgen Pharma Interview with CEO Dr Stephen Franklin.
IAmShareCrazy
28 Apr 2018
Rubbish Why buy a drug which will no doubt have side effects when you can grow your own broccoli sprouts or get sulphorane powder cheaply!
moorlaner
08 Dec 2017
it would have been nice........ if existing individual shareholders were given the option to buy more at a discount.thats all.
moorlaner
23 Nov 2017
wots going on anybody know???
si derman
19 Aug 2016
I'm In. Sorry to interrupt the flow of posts. Bought in on RNS day as I kinda liked what these guys are doing.Only did a small amount of research between 7am and opening, but thought I try my luck.Wish I'd found it a month or so back as it seams to have been slowly growing in strength and I guess when the news came it was already priced in. But hey ho. In now.Regards Si.
Simbr
01 Jun 2016
Evgen strong fy16 Evgen performed strongly during financial year 2016. The company was admitted to trade on AIM, with its placing being oversubscribed. Evgen made robust progress in relation to its main product SFX-01, as it completed two Phase II clinical trials. The company secured MHRA clinical trial approval for SAS (SFX-01 after subarachnoid haemorrhage), a Phase II clinical study that has commenced patient recruitment and treatment. During the period, Evgen increased its pipeline by in-licensing a range of novel analogues based on sulforaphane, the active principle of SFX-01. The company’s other programmes for metastatic breast cancer and multiple sclerosis are progressing as per schedule. Evgen’s cash and deposits increased, led by successful equity placing in the previous year. We believe the company is well placed to drive long-term growth, with all programmes on schedule and sufficient funds to complete the trials.Beufort's note from today..
forwardloop
26 Nov 2015
shares mag buy Courtesy of alliance trustHealthy outlook for EvgenBiotech is looking to use vegetable compound to treat cancerMark DunneAIM newcomer Evgen Pharma (EVG:AIM) could reward patient investors prepared to look ahead to a potentially transformative milestone 12 months in the future. The company plans to extract the health properties of broccoli, cabbage and other green leaf vegetables in the ‘cruciferous’ family. Drugs to fight cancer and repair the damage caused by subarachnoid haemorrhage, a type of stroke, are set to enter phase II clinical trials. An update on the progress of these trials is expected in late 2016. Management are confident because academic trials have produced encouraging data on the properties of the ‘sulfuraphane’ compound found within cruciferous veg. Because of its unstable nature this compound has historically been difficult for drugs companies to use. Evgen believes its Sulforadex technology fixes the problem, thus unlocking the commercial benefits provided by the compound. If it is right then success could translate into a licensing deal with significant milestone payments and eventually royalties if the drugs successfully pass phase III trials. If it is wrong the share price will likely crash. There is also the possibility that successful phase II trials could prompt a takeover bid from a larger player looking to own the Sulforadex technology and generate a pipeline of similar treatments. The phase II trials will run for 18 months from March 2016 and Evgen has enough cash to last until the summer of 2018, by which time a deal should be signed unless the treatments do not work. The Liverpool-based company raised £7 million at 37p per share from its initial public offering on 21 October – more than the £6.3 million it had initially planned to raise. The proceeds are funding the clinical trials as well as pre-clinical studies for a multiple sclerosis treatment. Northland Capital puts the firm’s fair value at a minimum of £60 million against a current market cap of £19.7 million. Evgen was established in 2007 by chief executive Stephen Franklin, who has two decades worth of experience on the commercial side of the life sciences industry. He helped float Provexis (PXS:AIM) on AIM in 2005. Shares says: BUY "At 27p this is a buy and hold share. Drug trial success could lead to lucrative partnership agreements or a takeover offer but investors need to understand the risks."
WALLY1947
21 Oct 2015
data this share has been trading since first thing this morning , so come on III, where are the prices ?
